Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2024-11-06 DOI:10.1038/s41571-024-00963-2

Joshua Drago, Shanu Modi

引用次数: 0

Abstract

The DESTINY-Breast06 trial investigated earlier and broader use of trastuzumab deruxtecan in patients with metastatic hormone-receptor-positive breast cancer, and demonstrated improvements in progression-free survival over standard chemotherapy. These data provide a meaningful advance; however, this strategy might not be right for all patients, and careful consideration is recommended before blanket use.

查看原文本刊更多论文

扩大T-DXd在转移性HR阳性乳腺癌中的应用：我们现在在哪里？

DESTINY-Breast06试验研究了在转移性激素受体阳性乳腺癌患者中更早和更广泛地使用曲妥珠单抗-德鲁司坦，结果显示，与标准化疗相比，无进展生存期有所改善。这些数据提供了一个有意义的进步；然而，这一策略可能并不适合所有患者，建议在一揽子使用前慎重考虑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.